TrialOncoimmunology2024

A phase 2, multicenter, open-label study of anti-LAG-3 ieramilimab in combination with anti-PD-1 spartalizumab in patients with advanced solid malignancies.

Chia-Chi Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.